GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CLS Holdings USA Inc (XCNQ:CLSH) » Definitions » Gross Profit

CLS Holdings USA (XCNQ:CLSH) Gross Profit : C$10.82 Mil (TTM As of Feb. 2024)


View and export this data going back to 2019. Start your Free Trial

What is CLS Holdings USA Gross Profit?

CLS Holdings USA's gross profit for the three months ended in Feb. 2024 was C$2.87 Mil. CLS Holdings USA's gross profit for the trailing twelve months (TTM) ended in Feb. 2024 was C$10.82 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. CLS Holdings USA's gross profit for the three months ended in Feb. 2024 was C$2.87 Mil. CLS Holdings USA's Revenue for the three months ended in Feb. 2024 was C$6.65 Mil. Therefore, CLS Holdings USA's Gross Margin % for the quarter that ended in Feb. 2024 was 43.17%.

CLS Holdings USA had a gross margin of 43.17% for the quarter that ended in Feb. 2024 => Durable competitive advantage

During the past 11 years, the highest Gross Margin % of CLS Holdings USA was 50.01%. The lowest was 38.37%. And the median was 46.29%.


CLS Holdings USA Gross Profit Historical Data

The historical data trend for CLS Holdings USA's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CLS Holdings USA Gross Profit Chart

CLS Holdings USA Annual Data
Trend May14 May15 May16 May17 May18 May19 May20 May21 May22 May23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.88 8.33 11.70 13.49 13.25

CLS Holdings USA Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.45 1.91 3.07 2.98 2.87

Competitive Comparison of CLS Holdings USA's Gross Profit

For the Drug Manufacturers - Specialty & Generic subindustry, CLS Holdings USA's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CLS Holdings USA's Gross Profit Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, CLS Holdings USA's Gross Profit distribution charts can be found below:

* The bar in red indicates where CLS Holdings USA's Gross Profit falls into.



CLS Holdings USA Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

CLS Holdings USA's Gross Profit for the fiscal year that ended in May. 2023 is calculated as

Gross Profit (A: May. 2023 )=Revenue - Cost of Goods Sold
=31.27 - 18.018
=13.25

CLS Holdings USA's Gross Profit for the quarter that ended in Feb. 2024 is calculated as

Gross Profit (Q: Feb. 2024 )=Revenue - Cost of Goods Sold
=6.65 - 3.779
=2.87

Gross Profit for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$10.82 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

CLS Holdings USA's Gross Margin % for the quarter that ended in Feb. 2024 is calculated as

Gross Margin % (Q: Feb. 2024 )=Gross Profit (Q: Feb. 2024 ) / Revenue (Q: Feb. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=2.87 / 6.65
=43.17 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


CLS Holdings USA  (XCNQ:CLSH) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

CLS Holdings USA had a gross margin of 43.17% for the quarter that ended in Feb. 2024 => Durable competitive advantage


CLS Holdings USA Gross Profit Related Terms

Thank you for viewing the detailed overview of CLS Holdings USA's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


CLS Holdings USA (XCNQ:CLSH) Business Description

Traded in Other Exchanges
Address
1800 Industrial Road, Suite 100, Las Vegas, NV, USA, 89102
CLS Holdings USA Inc is a diversified cannabis company that acts as an integrated cannabis producer and retailer through its Oasis Cannabis subsidiaries in Nevada and plans to expand to other states. CLS stands for Cannabis Life Sciences in recognition of the company's patented proprietary method of extracting various cannabinoids from the marijuana plant and converting them into products with a higher level of quality and consistency. The company's business model includes licensing operations, processing operations, processing facilities, sale of products, brand creation and consulting services. The company generates the majority of its revenues and corresponding accounts receivable from the sale of cannabis, and cannabis related products.